Key takeaways
Sotyktu (deucravacitinib) and Skyrizi (risankizumab) are both medications used to treat moderate-to-severe plaque psoriasis in adults. However, they belong to different medication classes and have important differences. Sotyktu is a tyrosine kinase 2 (TYK2) inhibitor taken orally once a day. It works by blocking a protein that causes inflammation. On the other hand, Skyrizi is an interleukin antagonist administered as an injection every 2 or 3 months after initial doses. It blocks proteins involved in inflammation, called interleukin-23 (IL-23). Skyrizi is also FDA-approved for psoriatic arthritis, ulcerative colitis, and Crohn's disease, while Sotyktu is only approved for plaque psoriasis. Both medications can increase the risk of an infection, including an upper respiratory infection. These medications are only available in a branded version.
